Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function

Prostate

Volumn 69, Issue 14, 2009, Pages 1586-1597

  Zolochevska, Olga ^a   Figueiredo, Marxa L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Androgen receptor; Androgen dependent; Apoptosis; Cdk2 inhibitor; Cellular growth

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2AP1; CYTOKINE; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DEMETHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REPORTER GENE; SIGNAL TRANSDUCTION;

ANDROGENS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 69449084550     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21007     Document Type: Article

References (33)

1. Schroder FH. Endocrine therapy for prostate cancer: Recent developments and current status. Br J Urol 1993;71(6):633-640. (Pubitemid 23188047)
2. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, Bartsch G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993;22(1):11-22. (Pubitemid 23075489)
3. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20(3-4):207-223. (Pubitemid 34595269)
4. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004;93(2):233-241. (Pubitemid 44264201)
5. Rigas AC, Robson CN, Curtin NJ. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 2007;26(55):7611-7619.
6. Jaruga-Killeen E, Rayford W. TNF receptor 1 is involved in the induction of apoptosis by the cyclin dependent kinase inhibitor p27Kip1 in the prostate cancer cell line PC-3. FASEB J 2005;19(1):139-141. (Pubitemid 40069944)
7. Katner AL, Hoang QB, Gootam P, Jaruga E, Ma Q, Gnarra J, Rayford W. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1). Prostate 2002;53(1):77-87. (Pubitemid 34966867)
8. Shintani S, Ohyama H, Zhang X, McBride J, Matsuo K, Tsuji T, Hu MG, Hu G, Kohno Y, Lerman M, Todd R, Wong DT. p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol 2000;20(17):6300-6307. (Pubitemid 30650216)
9. Shintani S, Mihara M, Terakado N, Nakahara Y, Matsumura T, Kohno Y, Ohyama H, McBride J, Kent R, Todd R, Tsuji T, Wong DT. Reduction of p12DOC-1 expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res 2001;7(9):2776-2782. (Pubitemid 32911384)
10. Figueiredo M, Kim Y, St John MAR, Wong DTW. p12CDK2AP1 gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer. Clin Cancer Res 2005;11(10):3939-3948. (Pubitemid 40685616)
11. Tao K, FangM, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008;8:228.
12. Sotsky Kent T, Yuan Z, Miller A, Weber TK. Deleted in oral cancer-1 expression upregulates proapoptosis elements in microsatellite-unstable human colorectal cancer. Ann Surg Oncol 2004;11(2):192-196. (Pubitemid 40486795)
13. Yuan Z, Sotsky Kent T, Weber TK. Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer. Oncogene 2003;22(40):6304-6310. (Pubitemid 37281661)
14. Matsuo K, Shintani S, Tsuji T, Nagata E, Lerman M, McBride J, Nakahara Y, Ohyama H, Todd R, Wong DT. p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase. FASEB J 2000;14(10):1318-1324. (Pubitemid 30439740)
15. Cwikla SJ, Tsuji T, McBride J, Wong DT, Todd R. doc-1-mediated apoptosis in malignant hamster oral keratinocytes. J Oral Maxillofac Surg 2000;58(4):406-414. (Pubitemid 30196132)
16. Kohno Y, Patel V, Kim Y, Tsuji T, Chin BR, Sun M, Bruce Donoff R, Kent R, Wong D, Todd R. Apoptosis, proliferation and p12(doc-1) profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol 2002;38(3):274-280. (Pubitemid 34442549)
17. Arencibia JM, Martin S, Perez-Rodriguez FJ, Bonnin A. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer. Int J Oncol 2009;34(2):457-463.
18. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 2001;98(26):15149-15154. (Pubitemid 34013984)
19. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A. Epithelial-restricted gene profile of primary cultures from human prostate tumors: A molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 2006;4(2):79-92.
20. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: A systems approach to disease. Cancer Res 2005;65(8):3081-3091. (Pubitemid 40524588)
21. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12(6):559-571. (Pubitemid 350199071)
22. Chandran UR, MaC, Dhir R, BiscegliaM, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007;7:64. (Pubitemid 47161402)
23. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72(11):8463-8471. (Pubitemid 28471781)
24. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995;23(4):628-633.
25. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther 2002;9(17):1155-1162.
26. Pluta K, Diehl W, Zhang XY, Kutner R, Bialkowska A, Reiser J. Lentiviral vectors encoding tetracycline-dependent repressors and transactivators for reversible knockdown of gene expression: A comparative study. BMC Biotechnol 2007;7:41. (Pubitemid 47342599)
27. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y, Mizokami A, Ito H, Yatani R, Shiraishi T. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000;80(12):1789-1796. (Pubitemid 32012748)
28. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8(10):1136-1144. (Pubitemid 35175969)
29. Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers WA, Cohen A, Lasonder E, Stunnenberg HG. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol 2006;26(3):843-851. (Pubitemid 43146480)
30. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006;66(12):1329-1338. (Pubitemid 44384309)
31. Niu Y, Altuwaijri S, Lai KP, WuCT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008;105(34):12182-12187.
32. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun 1998;248(2):361-367. (Pubitemid 28386427)
33. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997;126(1):59-73. (Pubitemid 27055548)